发明名称 |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
摘要 |
The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer. |
申请公布号 |
US2015183880(A1) |
申请公布日期 |
2015.07.02 |
申请号 |
US201514598664 |
申请日期 |
2015.01.16 |
申请人 |
Immunomedics, Inc. |
发明人 |
Chang Chien-Hsing;Losman Michele J.;Goldenberg David M. |
分类号 |
C07K16/28;A61K39/395;A61K51/10;A61K31/69;A61K31/7068;A61K47/48;A61K45/06;C07K16/30 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating cancer comprising administering to an individual with a cancer that expresses IGF-1R (insulin-like growth factor type I receptor) an anti-IGF-1R antibody or antigen binding fragment thereof, wherein said anti-IGF-1R antibody or fragment thereof comprises the heavy chain variable region complementarity determining region (CDR) sequences CDR1 (DYYMY, SEQ ID NO:1), CDR2 (YITNYGGSTYYPDTVKG, SEQ ID NO:2) and CDR3 (QSNYDYDGWFAY, SEQ ID NO:3) and the light chain variable region CDR sequences CDR1 (KASQEVGTAVA, SEQ ID NO:4), CDR2 (WASTRHT, SEQ ID NO:5) and CDR3 (QQYSNYPLT, SEQ ID NO:6). |
地址 |
Morris Plains NJ US |